nektar therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. nektar also partners with the top biopharmaceutical companies to bring new products to market. to date, nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.
Company profile
Ticker
NKTR
Exchange
Website
CEO
Howard Robin
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
INHALE THERAPEUTIC SYSTEMS INC, INHALE THERAPEUTIC SYSTEMS
SEC CIK
Corporate docs
Subsidiaries
Inheris Biopharma, Inc. ...
IRS number
943134940
NKTR stock data
Latest filings (excl ownership)
8-K
Other Events
17 Apr 24
D
$30.00 mm in equity / options, sold $30.00 mm, 1 investor
19 Mar 24
10-K
2023 FY
Annual report
5 Mar 24
8-K
Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results
4 Mar 24
8-K
Entry into a Material Definitive Agreement
4 Mar 24
8-K
Termination of a Material Definitive Agreement
16 Feb 24
8-K
Results of Operations and Financial Condition
10 Jan 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
27 Nov 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Nektar Therapeutics Reports Third Quarter 2023 Financial Results
7 Nov 23
Transcripts
NKTR
Earnings call transcript
2023 Q4
4 Mar 24
NKTR
Earnings call transcript
2023 Q3
7 Nov 23
NKTR
Earnings call transcript
2023 Q2
8 Aug 23
NKTR
Earnings call transcript
2023 Q1
9 May 23
NKTR
Earnings call transcript
2022 Q3
4 Nov 22
NKTR
Earnings call transcript
2022 Q2
4 Aug 22
NKTR
Earnings call transcript
2021 Q4
1 Mar 22
NKTR
Earnings call transcript
2021 Q3
5 Nov 21
NKTR
Earnings call transcript
2021 Q2
6 Aug 21
NKTR
Earnings call transcript
2021 Q1
7 May 21
Latest ownership filings
SC 13G
TCG Crossover GP II, LLC
15 Mar 24
3
DAVID KROIN
14 Mar 24
4
Jonathan Zalevsky
22 Feb 24
4
Mark Andrew Wilson
22 Feb 24
4
HOWARD W ROBIN
22 Feb 24
144
Notice of proposed sale of securities
20 Feb 24
144
Notice of proposed sale of securities
20 Feb 24
144
Notice of proposed sale of securities
20 Feb 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 64.92 mm | 64.92 mm | 64.92 mm | 64.92 mm | 64.92 mm | 64.92 mm |
Cash burn (monthly) | (no burn) | 3.40 mm | 15.30 mm | 24.22 mm | 14.04 mm | 16.94 mm |
Cash used (since last report) | n/a | 23.47 mm | 105.51 mm | 167.06 mm | 96.83 mm | 116.82 mm |
Cash remaining | n/a | 41.45 mm | -40.59 mm | -102.14 mm | -31.91 mm | -51.90 mm |
Runway (months of cash) | n/a | 12.2 | -2.7 | -4.2 | -2.3 | -3.1 |
Institutional ownership, Q3 2023
77.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 135 |
Opened positions | 17 |
Closed positions | 30 |
Increased positions | 32 |
Reduced positions | 47 |
13F shares | Current |
---|---|
Total value | 84.82 bn |
Total shares | 142.85 mm |
Total puts | 46.80 k |
Total calls | 8.10 k |
Total put/call ratio | 5.8 |
Largest owners | Shares | Value |
---|---|---|
Ra Capital Management | 18.70 mm | $11.14 bn |
Deep Track Capital | 18.40 mm | $10.96 bn |
Vanguard | 12.06 mm | $7.18 bn |
BLK Blackrock | 7.68 mm | $4.58 bn |
Acadian Asset Management | 7.63 mm | $4.55 bn |
Primecap Management | 7.20 mm | $4.29 bn |
D. E. Shaw & Co. | 6.12 mm | $3.65 bn |
Citadel Advisors | 5.63 mm | $3.35 bn |
Jacobs Levy Equity Management | 4.90 mm | $2.92 bn |
Monaco Asset Management SAM | 4.81 mm | $2.86 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 Feb 24 | Zalevsky Jonathan | Common Stock | Sell | Dispose S | No | No | 0.68 | 9,014 | 6.13 k | 265,025 |
20 Feb 24 | Mark Andrew Wilson | Common Stock | Sell | Dispose S | No | No | 0.68 | 7,606 | 5.17 k | 236,674 |
20 Feb 24 | Robin Howard W | Common Stock | Sell | Dispose S | No | No | 0.68 | 20,033 | 13.62 k | 879,889 |
13 Dec 23 | Robin Howard W | Stock Option Common Stock | Grant | Acquire A | No | No | 0.5 | 1,300,000 | 650.00 k | 1,300,000 |
News
Nektar Therapeutics Receives Letter That It Has Regained Compliance With Minimum Bid Price Requirement For Continued Listing On Nasdaq Capital Market - Filing
17 Apr 24
12 Health Care Stocks Moving In Thursday's Intraday Session
11 Apr 24
Jefferies Maintains Hold on Nektar Therapeutics, Raises Price Target to $1
6 Mar 24
Nektar Therapeutics Announces Initiation Of Phase 2b Clinical Study Evaluating Rezpegaldesleukin In Patients With Severe To Very Severe Alopecia Areata
5 Mar 24
Nektar Therapeutics Q4 2023 GAAP EPS $(0.22) Beats $(0.23) Estimate, Sales $23.89M Beat $18.05M Estimate
4 Mar 24
Press releases
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
22 Mar 24
Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results
4 Mar 24
Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX
4 Mar 24
Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference
27 Feb 24
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets
26 Feb 24